Skip to search formSkip to main contentSkip to account menu

L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein

Known as: L19-IL2 
An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after… 
Highly Cited
2015
Highly Cited
2015
Abstract The intratumoral injection of cytokines, in particular IL2, has shown promise for cutaneous melanoma patients with… 
Highly Cited
2014
Highly Cited
2014
Purpose: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect… 
Highly Cited
2014
Highly Cited
2014
Weide and colleagues show that intralesional therapy using the immunocytokine L19–IL2 elicited a high rate of clinical and… 
Highly Cited
2013
Highly Cited
2013
Systemic high-dose IL2 promotes long-term survival in a subset of metastatic melanoma patients, but this treatment is accompanied… 
Highly Cited
2012
Highly Cited
2011
Highly Cited
2011
Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor… 
Highly Cited
2009
Highly Cited
2009
The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy… 
Highly Cited
2008
Highly Cited
2008
Purpose: Effective control of pancreatic cancer has been hampered primarily by the lack of tumor specificity of current treatment…